干细胞在慢性阻塞性肺疾病治疗中的作用  

Role of stem cells therapy in chronic obstructive pulmonary disease

作　　者：李亚清[1] 严建平[1] 许武林[1] 

机构地区：[1]浙江省人民医院呼吸内科,杭州110014

出　　处：《国际呼吸杂志》2013年第19期1486-1490,共5页International Journal of Respiration

基　　金：国家自然科学基金（81000016）资助

摘　　要：慢性阻塞性肺疾病（chronic obstructive pulmonary disease，COPD）是一种以进行性不可逆性气流受限为特征的慢性气道炎症性疾病，具有全球性高发病率和病死率。如何修复损伤的肺组织、使丢失的肺泡再生是COPD治疗的关键所在。肺脏再生治疗包括刺激内源性成体肺干细胞及引入胚胎干细胞、骨髓源性干细胞或羊水源性间质干细胞等外源性干细胞两种途径。目前已有全反维甲酸激动剂及骨髓间质干细胞治疗COPD的临床试验研究，其安全性及有效性仍有待于观察。随着对干细胞定向分化及调控机制的深入研究，干细胞治疗将为COPD等疾病的治疗带来新希望。Chronic obstructive pulmonary disease （COPD） is a leading global cause of morbidity and mortality, which is characterized by airflow limitation that is not fully reversible but usually progressive. The key to COPD is how to repair damaged lung tissue and regenerate the lost alveoli. The strategies to reverse the structural and functional deficits in COPD include in endogenous cell therapy and the delivery of exogenous stem cells such as embryonic stem cells, bone marrow-derived stem cells and amniotic fluid mesenchymal stem cells. There are currently two trials in progress concerning patients with COPD, one of a specific all-trans retinoic acid receptor agonist and another one using bone marrow mesenchymal stem cells. The safety and efficacy still remains to be observed. As the regulatory mechanisms of the directed differentiation of stem cells are studied in-depth, stem cells therapy will bring a new hope for the treatment of COPD.

关 键 词：慢性阻塞性肺疾病 肺泡上皮细胞 干细胞 肺再生 

分 类 号：R563.9[医药卫生—呼吸系统]